Business Insider1d
Truist Financial Sticks to Its Buy Rating for Arcellx Inc (ACLX)
Truist Financial analyst Asthika Goonewardene reiterated a Buy rating on Arcellx Inc (ACLX – Research Report) today and set a price target of $136.00. The company’s shares closed yesterday at ...
Zacks.com on MSN5d
Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar?
Arcellx (ACLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
ETF Daily News1d
Arcellx (NASDAQ:ACLX) Price Target Raised to $115.00 at Piper Sandler
Arcellx (NASDAQ:ACLX – Free Report) had its price target raised by Piper Sandler from $91.00 to $115.00 in a report issued ...
Arcellx issues updates on anito-cel clinical trials
Arcellx (NASDAQ:ACLX) announced an update for its Phase 3 iMMagine-3 study and plans to present Phase 1 and 2 data for its ...
FierceBiotech7d
ASH: New Gilead-Arcellx data build CAR-T's case against Carvykti in advanced multiple myeloma
Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...
BioSpace18h
Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more
BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.
Arcellx (ACLX) Surged in Q3. Here’s Why
Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A ...
Business Wire5d
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...
BioSpace6d
Gilead, Arcellx Tout Best-in-Class Potential for CAR T Therapy in Multiple Myeloma
Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...
Arcellx Inc’s Anito-cel: Promising CAR-T Therapy with Strategic Partnerships and Strong Financial Position
Leerink Partners analyst Daina Graybosch has maintained their bullish stance on ACLX stock, giving a Buy rating on November 8. Daina ...
Business Wire8d
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition ...
--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable ...